Idasanutlin (15) (Fig. 5) is a nutlin derivative that binds to Mdm2 and prevents p53–Mdm2 interaction [35], and a phase III clinical trial of idasanutlin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia was conducted. Here, MDM2 is linked to acute myeloid leukemia.